Product Information

EPIVIR 300 MG TABLET is a brand product labeled by ViiV Healthcare Company, priced at $13.2940 per EA under NDC 49702020413. Its NADAC has been published 61 times since Dec 18, 2013.

FDA first approved this application on Nov 17, 1995. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the lamivudine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

Price Statistics

The NADAC for EPIVIR 300 MG TABLET has been published 61 times since Dec 18, 2013, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 90% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.